Technical Analysis for DMPI - DelMar Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 1.86 -17.33% -0.39
DMPI closed down 17.33 percent on Friday, May 24, 2019, on 2.12 times normal volume. The bears made the stock sink to a new 52-week low.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical DMPI trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Gapped Down Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
1,2,3 Retracement Bearish Bearish Swing Setup -17.33%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -17.33%
Inside Day Range Contraction -17.33%
Wide Bands Range Expansion -17.33%
Pocket Pivot Bullish Swing Setup -33.33%

Older signals for DMPI ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
DelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer. VAL-083 is being evaluated in a Phase II clinical trial for the treatment of refractory GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Its drug discovery research focuses on identifying validated clinical and commercial-stage compounds, and establishing a scientific rationale for development in orphan drug indications. VAL-083 is an alkylating agent, which crosses the blood-brain-barrier (BBB).
Medicine Cancer Clinical Medicine Treatment Of Cancer Oncology Chemotherapy Drug Discovery Cancer Treatments Antineoplastic Drugs Drug Development Glioblastoma Leukemia Brain Tumor Lung Cancer Brain Cancer Glioblastoma Multiforme
Is DMPI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 9.7
52 Week Low 1.65
Average Volume 79,598
200-Day Moving Average 4.7146
50-Day Moving Average 3.6668
20-Day Moving Average 2.968
10-Day Moving Average 2.376
Average True Range 0.4867
ADX 49.87
+DI 12.3882
-DI 38.6172
Chandelier Exit (Long, 3 ATRs ) 2.5399
Chandelier Exit (Short, 3 ATRs ) 3.1101
Upper Bollinger Band 4.2738
Lower Bollinger Band 1.6622
Percent B (%b) 0.08
BandWidth 87.991914
MACD Line -0.4131
MACD Signal Line -0.3469
MACD Histogram -0.0662
Fundamentals Value
Market Cap 40.09 Million
Num Shares 21.6 Million
EPS -0.74
Price-to-Earnings (P/E) Ratio -2.51
Price-to-Sales 0.00
Price-to-Book 77.27
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.52
Resistance 3 (R3) 2.52 2.31 2.41
Resistance 2 (R2) 2.31 2.14 2.30 2.37
Resistance 1 (R1) 2.08 2.03 1.97 2.08 2.34
Pivot Point 1.87 1.87 1.81 1.86 1.87
Support 1 (S1) 1.64 1.70 1.54 1.64 1.38
Support 2 (S2) 1.43 1.59 1.43 1.35
Support 3 (S3) 1.20 1.43 1.31
Support 4 (S4) 1.20